文献速递淋巴瘤造血干细胞移植与细胞治疗

维布妥昔单抗联合纳武利尤单抗治疗复发难治霍奇金淋巴瘤:3年研究结果

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
PubMed 文献 · Blood · 2021-01-01

这项1-2期研究评估维布妥昔单抗(BV)联合纳武利尤单抗(Nivo)作为复发/难治经典型霍奇金淋巴瘤(cHL)的首个挽救方案。91例患者客观缓解率85%,完全缓解率67%;中位随访34.3个月,3年无进展生存率77%,直接接受自体干细胞移植者91%,3年总生存率93%。

要点

  • BV联合Nivo作为首个挽救方案在r/r cHL中显示持久的疗效。
  • 直接接受ASCT的患者3年PFS率达91%,无额外毒性担忧。
  • 常见不良事件为恶心和输注相关反应,均为1-2级。

核心结论

  • BV联合Nivo作为首个挽救方案在r/r cHL中显示持久疗效,尤其对直接移植者PFS显著,且无额外毒性。

研究设计与样本

  • 1-2期研究,评估BV联合Nivo作为r/r cHL的首个挽救治疗,分为第1、2部分(第1周期交错给药,第2-4周期同日给药)和第3部分(全部4周期同日给药)。

主要发现

  • 客观缓解率(ORR;N=91)为85%,完全缓解(CR)率67%。
  • 中位随访34.3个月,3年无进展生存(PFS)率为77%(95% CI 65%-86%),直接接受ASCT者为91%(95% CI 79%-96%)。
  • 3年总生存率为93%(95% CI 85%-97%)。
  • ASCT前最常见不良事件为恶心(52%)和输注相关反应(43%),均为1或2级。
  • 16例患者(18%)发生需全身皮质类固醇治疗的免疫相关不良事件。

关键数值与推荐

  • 肿瘤CD30中位基因表达在缓解者中高于未缓解者。
  • 外周血免疫特征与活化T细胞反应一致。

临床怎么用

  • BV联合Nivo可作为r/r cHL的首个挽救方案,缓解后可考虑直接进行ASCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. Overall survival at 3 years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow-up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS, especially in patients who proceeded directly to transplant, without additional toxicity concerns. This trial was registered at www.clinicaltrials.gov as #NCT02572167.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021. PMID: 33827139. doi:10.1182/blood.2020009178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。